Abstract
This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.
| Original language | English |
|---|---|
| Pages (from-to) | 46-57 |
| Number of pages | 12 |
| Journal | Topics in Spinal Cord Injury Rehabilitation |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1 2009 |
Fingerprint
Keywords
- Dyslipidemia
- Glucose intolerance
- Metabolic syndrome
- Pharmacotherapy
ASJC Scopus subject areas
- Clinical Neurology
- Rehabilitation
- Physical Therapy, Sports Therapy and Rehabilitation
Cite this
Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents. / Goldberg, Ronald B.
In: Topics in Spinal Cord Injury Rehabilitation, Vol. 14, No. 3, 01.12.2009, p. 46-57.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents
AU - Goldberg, Ronald B
PY - 2009/12/1
Y1 - 2009/12/1
N2 - This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.
AB - This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.
KW - Dyslipidemia
KW - Glucose intolerance
KW - Metabolic syndrome
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=59849091218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59849091218&partnerID=8YFLogxK
U2 - 10.1310/sci1403-46
DO - 10.1310/sci1403-46
M3 - Article
AN - SCOPUS:59849091218
VL - 14
SP - 46
EP - 57
JO - Topics in Spinal Cord Injury Rehabilitation
JF - Topics in Spinal Cord Injury Rehabilitation
SN - 1082-0744
IS - 3
ER -